Navigation Links
Monoclonal antibodies show promise in treatment of blood cancer

Immunologists at Duke University Medical Center have found that a new monoclonal antibody that targets immune system B cells could be a pioneering treatment for leukemias, autoimmune diseases and transplant rejection//.

B cells are the main producers of antibodies, the body's defense mechanism against invading antigens. But the uncontrolled production of these B cells is responsible for leukemias such as multiple myeloma and acute lymphoblastic leukemia and autoimmune diseases like rheumatoid arthritis and lupus. The findings of the study have been published in the online Early Edition of the Proceedings of the National Academy of Sciences for the week October 10, 2005.

Professor and Chair of Immunology Thomas Tedder, Ph.D., Norhito Yazawa, Yasuhito Hamaguchi and Jonathan Poe in Tedder's laboratory are the co-authors of this report. Basically, monoclonal antibodies are directed against specific proteins. In this study, the Duke researchers targeted a surface protein called CD19, which is found on the B cells. When this was administered to laboratory mice, the researchers found that this reduced the number of B cells greatly. Significantly they also found that this monoclonal antibody behaved aggressively against B cell tumors. In 10 mice with malignant B cell lymphomas, the monoclonal antibody prevented the appearance of tissue tumor circulating cells for seven weeks. In contrast untreated mice died in three weeks. "We were actually quite shocked at how effectively CD19 mAb-treatments prevented malignant B cell expansion," said Tedder. "Treatment of such tumors in mouse models is extraordinarily difficult." Based on their findings, the researchers conclude, "In addition, this treatment could greatly aid transplant patients who require multiple organ transplants because they develop a humoral antibody response to their transplanted organs, or they already have preformed antibodies that prevent them from accepting some donor grafts."
'"/>




Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
3. Monoclonal Antibody based system for Anthrax detection
4. Monoclonal Antibody Reduces Exacerbations in Asthmatics
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Mutating viruses helps produce antibodies
7. Hybrid antibodies to protect from small pox infection
8. Gene Therapy shows promise in treating Hemophilia
9. Leukemia pill shows promise against stomach cancer
10. Stent shows promise in keeping arteries open
11. Drug to treat lung cancer shows promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... speaker, trainer and author Ray Clarke poses a question as a challenge for ... In his book, "Being in the Being" (published by Partridge Singapore), Clarke explores ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... multi-specialty practice Village Family Practice , will be presenting at the 2016 ... in Las Vegas, Nev. , During his session, “ Coding for Care: ...
(Date:2/11/2016)... ... 11, 2016 , ... The annual list showcases the 20 Most Promising SharePoint ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members ... is to recognize and promote technology entrepreneurship. , The survey was made at ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions and the ... achieved through NPS and Dyax acquisitions and the announced combination ... through NPS and Dyax acquisitions and the announced combination with ... robust pipeline in Shire , s history   ... pipeline in Shire , s history   ...
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
Breaking Medicine Technology: